Showing 1381-1390 of 1735 results for "".
- CDC Expands Negative COVID-19 Test Requirement to All Air Passengers Entering the United Stateshttps://modernod.com/news/cdc-expands-negative-covid-19-test-requirement-to-all-air-passengers-entering-the-united-states/2478761/The Centers for Disease Control and Prevention is expanding the requirement for a negative COVID-19 test to all air passengers entering the United States. Testing before and after travel is a critical layer to slow the in
- AAO: Top Four Issues Threatening Ophthalmology’s Financial Stabilityhttps://modernod.com/news/aao-top-four-issues-threatening-ophthalmologys-financial-stability/2480440/<
- Top Contact Lens Experts Dispel Misinformation Regarding Coronavirushttps://modernod.com/news/top-contact-lens-experts-dispel-misinformation-regarding-coronavirus/2477381/Three of the world’s most published researchers in eye health are responding to misinformation circulating regarding contact lens and spectacles/glasses wear amidst Novel Coronavirus/COVID-19 pandemic. Lyndon Jones, director of the Centre for Ocular Research & Education (CORE) at the U
- Mount Sinai Health System Top Presentations and Abstracts From AAOhttps://modernod.com/news/mount-sinai-health-system-top-presentations-and-abstracts-from-aao/2479715/Mount Sinai Health System in New York City made several presentations and poster sessions at the American Academy of Ophthalmology meeting in Chicago. Below is a summary of the abstracts and presentations: “Long-term Efficacy of Fractionated Conformal Radiotherapy for th
- Harrow Launches 'Vevye Access for All' to Reduce Patient Barriers for Dry Eye Disease Treatmenthttps://modernod.com/news/harrow-launches-vevye-access-for-all-reducing-patient-barriers-for-dry-eye-disease-treatment/2482703/Harrow announced 'Vevye Access For All' – a new initiative that aims to reduce patient barriers to dry eye disease treatment. Harrow partnered with specialty pharmacy PhilRx to offer Vevye (cyclosporine ophthalmic solution) 0.1% for eligible patients at $59 a bottle. The g
- Dopavision Provides Clinical Trial Update and Announces All MyopiaX-1 Trial Sites Are Activehttps://modernod.com/news/dopavision-provides-clinical-trial-update-and-announces-all-myopiax-1-trial-sites-are-active/2481699/Dopavision announced an update on its MyopiaX-1 trial (NCT04967287). All clinical trial centers are now open and are actively screening and enrolling study participants, providing trial access to eligible children with myopia across Germany, Spain, the Netherlands, and the United Kingdom.
- Gemini Therapeutics Announces GEM103 Meets All Endpoints in Phase 1 Clinical Studyhttps://modernod.com/news/gemini-therapeutics-announces-gem103-meets-all-endpoints-in-phase-1-clinical-study/2478546/Gemini Therapeutics announced that the phase 1 study of GEM103, the company’s investigational treatment for dry AMD, met all its endpoints. Results demonstrate that in 12 patients receiving a single intravitreal (IVT) injection of GEM103, there were no dose-limiting toxicities or treatment-
- FDA Expands Emergency Use for Gilead’s Veklury to All Hospitalized COVID-19 Patientshttps://modernod.com/news/fda-expands-emergency-use-for-gileads-veklury-to-all-hospitalized-covid-19-patients/2478218/The FDA has broadened the scope of an existing emergency-use authorization (EUA) for Gilead Sciences’ Veklury (remdesivir) to include treatment of all hospitalized adult and paediatric patients with suspected or laboratory-confirmed COVID-19, regardless of the severity of their disease. In
- Moderna’s COVID-19 Vaccine Candidate Induces “Robust” Response In All Patients Testedhttps://modernod.com/news/modernas-covid-19-vaccine-candidate-induces-robust-response-in-all-patients-tested/2478023/The NEJM published an interim analysis Tuesday of an ongoing phase 1 trial showing that Moderna’s experimental COVID-19 vaccine mRNA-1273 induced anti–SARS-CoV-2 immune responses in all participants, with the authors saying there were “no trial-limiting safety concerns.”
- Major League Soccer All-Star Alecko Eskandarian to Speak at Annual NORA Conferencehttps://modernod.com/news/major-league-soccer-all-star-alecko-eskandarian-to-speak-at-annual-nora-conference/2476364/Two-time Major League Soccer (MLS) All-Star Alecko Eskandarian will be the key-note speaker at the Neuro-Optometric Rehabilitation Association, International (NORA) 28th annual General Conference (September 21-22) at the Embassy Suites by Hilton Scottsdale Resorts, Scottsdale, Arizona.